Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 47

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 47
---
 or programs through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidates or program.

We face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.

We operate in the highly competitive biotechnology and biopharmaceutical industries, facing significant competition from major pharmaceutical companies, established and emerging biotechnology firms, universities, and research institutions, both domestically and internationally, with many possessing greater financial, technical, and human resources. In Parkinson’s disease, we compete against widely used treatments like levodopa/carbidopa, while in Alzheimer’s disease, we face competition from approved and late-stage therapies like Biogen’s Aduhelm, Eli Lilly’s donanemab, and Eisai’s Leqembi, alongside novel candidates like Cognition Therapeutics’ CT1812 and Anavex’s 2-73. In rare diseases such as MPS-1, Friedreich’s ataxia, and MELAS, we compete with established therapies like Sanofi Genzyme’s Aldurazyme and Reata’s SKYCLARYS, as well as emerging treatments from companies like RegenexBio, Sigilon Therapeutics, Larimar Therapeutics, Cyclerion Therapeutics, and Abliva AB. Competitors’ ability to develop safer, more effective, or less expensive products, secure faster regulatory approvals, or establish stronger market positions could reduce or eliminate our commercial opportunities, rendering our product candidates less competitive or obsolete.

Interim, topline and preliminary data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as the interim data from our Phase I clinical trial of JOTROL™. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may